SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LEXG-Lexicon Genetics
LXRX 1.250-12.6%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who started this subject3/13/2001 1:57:08 PM
From: nigel bates   of 254
 
Here's hoping they find a cure for writer's cramp...

THE WOODLANDS, Texas, March 12 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today that Robert J. Lefkowitz, M.D., has been elected to the Lexicon Board of Directors.
Dr. Lefkowitz is the James B. Duke Professor of Medicine, Professor of Biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. He is a member of the National Academy of Sciences.
``Bob Lefkowitz is an outstanding scientist, educator and leader, and I look forward to working with him on the Lexicon board,'' said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. ``Through his work with beta adrenergic receptors -- the molecules that translate hormonal signals into cellular responses in the heart and other organs throughout the body -- he has essentially defined receptor biology. His work has led to significant breakthroughs in understanding the role of G protein-coupled receptors (GPCRs) in regulating heart rate, basic endocrine function, the senses of sight, smell and taste and pain tolerances. At the same time, sequence homology data suggest that there are hundreds, perhaps thousands, of GPCRs still to be identified in the human genome. We believe the power of our patented technology and our drug discovery program will be well served by Bob's vision for translating biology and biochemistry knowledge into improved treatment for human disease.''
Dr. Lefkowitz has served on a number of scientific advisory boards, including the Genentech scientific advisory board, and was a member of the founding scientific advisory board for Affymax. He has consulted widely in the pharmaceutical industry, and has worked with both SmithKline Beecham and Abbott Laboratories, among others. During his 35 years as a researcher and clinician, Dr. Lefkowitz has authored or co-authored more than 700 publications. He has also received more than 40 honors and awards from various research institutions, academic societies and foundations. He received his B.A. from Columbia University and his M.D. from Columbia University College of Physicians and Surgeons...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext